INNODIA is a global partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise and 2 patient organisations, bringing their knowledge and experience together with one common goal: “To fight type 1 diabetes“.
- Newly diagnosed T1D are aged 1-45yrs, and within their first 6 weeks of diagnosis
- First degree family members (including half-siblings) of someone with T1D (who was diagnosed under the age of 45yrs) and aged 1-45yrs
With this data we can study the evolution of the disease in these individuals and develop new ways to predict the risk for relatives for developing the disease and eventually find a cure for those already diagnosed with the disease.
Thanks to the INNODIA research we will be able to better understand the relationship between changes in β-cell function, immune profiles, genetic and environmental factors and their role in the onset of the disease.
A second major goal of INNODIA is to initiate clinical intervention studies. Clinical Trials VER-A-T1D, MELD-ATG, CFZ533 and IMPACT are due to start in 2020. Here again, pharmaceutical companies being part of INNODIA join forces with leading academic clinical researchers to prove the effectiveness of these potential new therapeutic agents.
Newly diagnosed T1D people and T1D relatives are encouraged to participate in this study.